Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,238 INR | -0.45% | +2.11% | -0.69% |
Apr. 02 | Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer | CI |
Apr. 02 | Pfizer Limited Appoints Amit Agarwal as Whole-Time Director, Designated as Executive Director Finance | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.82 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.28% | 2.33B | B- | ||
+33.25% | 704B | C+ | ||
+28.59% | 577B | B | ||
-3.55% | 348B | C+ | ||
+18.16% | 327B | B- | ||
+4.36% | 288B | C+ | ||
+14.81% | 234B | B+ | ||
+4.93% | 198B | B- | ||
-9.78% | 194B | A+ | ||
-3.69% | 147B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PFIZER Stock
- Ratings Pfizer Limited